BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Beijing Biostar Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Beijing Biostar Pharmaceuticals's
  drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06683703-2272@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Utidelone: Phase 2 readout est. (NCT06683703)
DESCRIPTION:Utidelone\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Utide
 lone Injection Combined with Bevacizumab Injection for Non-small Cell Lung
  Cancer Patients with Brain Metastases\nEstimated primary completion: 1 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/utidelon
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 683703
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06730581-2272@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Utidelone: Phase 2 readout est. (NCT06730581)
DESCRIPTION:Utidelone\, phase 2.\nStudy: Utidelone Capsule Monotherapy for 
 Patients with Advanced Solid Tumors\nEstimated primary completion: 31 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/utidelone#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0673
 0581
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764940-2272@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Utidelone: Phase 2 readout est. (NCT06764940)
DESCRIPTION:Utidelone\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitab
 ine in HER2-negative Breast Cancer Patients With Brain Metastases\nEstimat
 ed primary completion: 15 January 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/utidelone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06764940
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07044349-2272@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Utidelone: Phase 2 readout est. (NCT07044349)
DESCRIPTION:Utidelone\, phase 2.\nStudy: Phase II Clinical Study of Utidelo
 ne Capsule (UTD2) in Patients With Advanced Epithelial Ovarian\, Fallopian
  Tube\, or Primary Peritoneal Cancer\nEstimated primary completion: March 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/utidelone#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07044349
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684456-2272@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Utidelone: Phase 3 readout est. (NCT07684456)
DESCRIPTION:Utidelone\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Pat
 ients With HER-2 Negative Advanced Breast Cancer\nEstimated primary comple
 tion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/u
 tidelone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07684456
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06841679-2272@assetmemo.bio
DTSTAMP:20261121T005001Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Utidelone: Phase 2/3 readout est. (NCT06841679)
DESCRIPTION:Utidelone\, phase 2/3.\nStudy: Utidelone Capsule Combined With 
 Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment 
 of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma\nEsti
 mated primary completion: 1 September 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/utidelone#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06841679
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
